Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges

doi:10.3748/wjg.v31.i15.104901

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (233)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

107

Figures (1-1)

Tables (1-2)

Sum=151

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=65

Publishing Process of This Article

Item

Count

Browse

Download

Sum=7

Apr 21, 2025 (publication date) through Apr 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Apr 21, 2025; 31(15): 104901
Published online Apr 21, 2025. doi: 10.3748/wjg.v31.i15.104901

Open in New Tab Full Size Figure Download Figure

Figure 1 Schematic presentation of multiple conversion treatment options for intrahepatic cholangiocarcinoma. TACE: Transarterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; TARE: Transarterial radioembolization; PD-1: Programmed cell death 1; PD-L1: Programmed cell death-ligand 1; FGFR2: Fibroblast growth factor receptor 2; IDH1: Isocitrate dehydrogenase-1; HER2: Human epidermal growth factor receptor 2; NTRK: Neurotropic tyrosine kinase receptor; RET: Rearranged during transfection; Gem: Gemcitabine; Cis: Cisplatin; Gemox: Gemcitabine and oxaliplatin; FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; ALPPS: Associating liver partition and portal vein ligation for staged hepatectomy; PVE: Portal vein embolization.

Citation: Liu JJ, Zhou M, Yuan T, Huang ZY, Zhang ZY. Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges. World J Gastroenterol 2025; 31(15): 104901
URL: https://www.wjgnet.com/1007-9327/full/v31/i15/104901.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i15.104901